Result Of Phase 3 Study For Prestige Biopharma's Herceptin Biosimilar, Hd201(Tuznue®), Published In JAMA Oncology
11/03/2022 10:52
March 11 (Reuters) - Prestige Biopharma Ltd 950210.KS :
* PRESTIGE BIOPHARMA LTD - RESULT OF PHASE 3 STUDY FOR
PRESTIGE
BIOPHARMA'S HERCEPTIN BIOSIMILAR, HD201(TUZNUE®), PUBLISHED IN
JAMA ONCOLOGY
* PRESTIGE BIOPHARMA LTD - STUDY MET ITS PRIMARY ENDPOINT
(TPCR)
AND SHOWED EQUIVALENT EFFICACY AND COMPARABLE SAFETY PROFILE
Source text for Eikon: ID:nBw26wm6Ma
Further company coverage: 950210.KS
Recent news on Prestige Biopharma
See all newsBrief: Prestige Biopharma Wins 2 Billion Won Order
Brief: Prestige Biopharma Receives Final Market Approval From The European Commission For Drug ‘Tuznue,’ For The Treatment Of Breast Cancer And Metastatic Gastric Cancer
Australia's Imagion Biosystems rises on MOU for cancer detection device
Brief: Prestige Biopharma And Intas Pharmaceuticals Announce Partnership To Commercialize Bevacizumab Biosimilar
Brief: Prestige Biopharma Signs Pharmaceutical Contract Manufacturing Agreement With Benevira Inc